Shares in Valneva SE rose by as much as 32% during early trading April 30 on news that Pfizer Inc. is paying $130 million up front to in-license its Lyme disease candidate vaccine, VLA-15. Valneva could also receive a further $35 million in development milestones and $143 million in early commercial milestones, as well as tiered sales royalties starting at 19%.